News

The study programme follows pre-clinical research results and comprises at least three small scale clinical trials evaluating various metabolic parameters. The first Phase IIa study to commence is

The FDA’s Neutroval CRL is for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for

Results from the Phase III study showed that Lixisenatide once-daily in combination with basal insulin (with or without sulfonylurea) significantly improved glycemic control. Sanofi-aventis R&D executive vice president

The DispersinB topical wound spray was manufactured by Therapure Biopharma (Mississauga, ON, Canada), under current Good Manufacturing Practices (cGMP). DispersinB is an antibiofilm enzyme, which inhibits and disperses

The base award is valued at $5.4m over 17 months; with provisions for renewal at the NCI’s option. The contract is partly funded by the American Recovery and

Boehringer, with its new production facility, is doubling its annual production capacity to 20 million inhalation devices (Respimat Soft Mist Inhaler). The expansion also involves the creation of

Biotron claims that BIT225 is a new drug with the potential to improve treatment options for HCV patients. The Phase IIa clinical trial is a combination study of

PPD, which already has offices in Moscow, Smolensk and St Petersburg, intends to strengthen its presence in Russia with this new office. PPD is a contract research organisation

Wellbutrin XL (bupropion hydrochloride) is an antidepressant of the aminoketone class and is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Wellbutrin